buserelin
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00528866 | Apr 2008 → Dec 2013 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01603420 | Jul 2012 → May 2014 | prostate cancer | Proton Collaborative Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 34 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT01492972 | Jan 2012 → Dec 2027 expected | prostate cancer | Proton Collaborative Group | Recruiting | No outcome recorded |
| Phase 3 | NCT01368588 | Jul 2011 → Apr 2025 overdue | prostate cancer | Radiation Therapy Oncology Group | Active not recruiting | Missed primary |
| Phase 3 | NCT00936390 | Sep 2009 → Oct 2020 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00567580 | Feb 2008 → Jul 2018 | prostate cancer | Radiation Therapy Oncology Group | Unknown | Met primary |
| Phase 43 trials · 2 missed | ||||||
| Phase 4 | NCT03946722 | Aug 2020 → Aug 2023 | adenomyosis | University College, London | Unknown | No outcome recorded |
| Phase 4 | NCT00627406 | Jan 2009 → Dec 2011 | ovarian hyperstimulation syndrome | Regionshospitalet Viborg, Skive | Completed | Missed primary |
| Phase 4 | NCT00461916 | May 2005 → Dec 2006 | infertility disorder | Tehran University of Medical Sciences | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT05567731 | Oct 2022 → Dec 2023 | infertility disorder | Tanta University | Completed | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 1 | NCT00054106 Background | Dec 2002 → Sep 2004 | prostate cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00823121 Comparator | Aug 2008 → Feb 2009 | — | Yazd Research & Clinical Center for Infertility | Unknown | No outcome recorded |
| Phase 1/2 | NCT00823004 Comparator | Jun 2008 → Feb 2009 | ovarian hyperstimulation syndrome | Yazd Research & Clinical Center for Infertility | Completed | No outcome recorded |
| Phase 2 | NCT07553988 Background | Oct 2024 → May 2026 overdue | prostate carcinoma | R-Pharm International, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05050084 Background | Dec 2021 → Nov 2026 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513717 Background | Jan 2021 → Dec 2033 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01546987 Background | May 2012 → Nov 2021 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00651326 Comparator | Jun 2008 → May 2010 | prostate cancer | NCIC Clinical Trials Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00288080 Background | Dec 2005 → Apr 2014 | prostate cancer | Radiation Therapy Oncology Group | Completed | Met primary |
| Phase 3 | NCT00004054 Background | Jan 2000 → Apr 2010 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00003653 Comparator | Jan 1999 → Oct 2010 | prostate cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00002633 Comparator | Feb 1995 → Sep 2011 | prostate cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 4 | NCT01816789 Background | Mar 2013 → Jul 2016 | — | Andros Day Surgery Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT01888744 Comparator | Sep 2010 → Jun 2013 | infertility disorder | University Hospital Brussels | Completed | No outcome recorded |
| Phase 4 | NCT01213147 Comparator | Apr → Aug 2009 | pregnancy disorder | Yazd Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00830492 Comparator | Jan → Dec 2008 | ovarian hyperstimulation syndrome | Yazd Research & Clinical Center for Infertility | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | buserelin | “All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing...” NCT01368588 ↗23“Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.” NCT01603420 ↗ “Start GnRH analogue (Buserelin 0.5ml subcutaneously once daily) on day 21 of downregulation cycle and reduce to 0.2ml on day 1 of bleed.” NCT03946722 ↗ “LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration” NCT00528866 ↗ “luteinizing hormone-releasing hormone (LHRH) agonist (e.g., leuprolide acetate, goserelin, buserelin, or triptorelin)” NCT00288080 ↗ “Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months” NCT00004054 ↗ “LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix.” NCT00936390 ↗ “* Buserelin: lyophilisate for solution for intramuscular injection, 3.75 mg” NCT07553988 ↗ “leuprolide, goserelin, buserelin, or triptorelin” NCT01492972 ↗ |
| Known as | BSRL | “luteinizing hormone-releasing hormone (LHRH) analog (buserelin [BSRL], goserelin [ZDX], or leuprolide [LEUP])” NCT00003653 ↗ |
| Known as | buserelin acetate | “Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application.” NCT05567731 ↗1“buserelin acetate, Suprefact® 600 μg daily intranasal” NCT01888744 ↗ |
| Known as | suprefact | “Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first...” NCT00830492 ↗ |
| Route | Subcutaneous | “Buserelin 6.3mg SC (abd) Q8wk” NCT00002633 ↗ |